GlassScriptPhysician profile
Kellie D Coffey
NPI 1063637270
$2,049.37
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $721 · 2023: $453 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.68 | 2021-2024 | |
| Novo Nordisk INC | $347.46 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $160.83 | 2021-2023 | Repatha |
| Lilly USA, LLC | $142.37 | 2021-2024 | Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $127.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.05 | 2021-2023 | Jardiance |
| Pfizer INC. | $97.00 | 2021-2024 | |
| Abbott Laboratories | $96.15 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $54.34 | 2022 | |
| Currax Pharmaceuticals LLC | $50.87 | 2021-2022 | |
| Esperion Therapeutics, INC. | $46.59 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $46.45 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $45.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.52 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $30.02 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.00 | 2022 | |
| Dexcom, INC. | $24.93 | 2022 | |
| Corcept Therapeutics | $22.94 | 2024 | Korlym |
| Phadia US INC. | $22.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.71 | 2021 | |
| Insulet Corporation | $17.11 | 2023 | Omnipod |
| Allergan, INC. | $16.85 | 2021 | |
| Genentech USA, INC. | $14.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.